KS tumor responses by dose of IL-12
IL-12, ng/kg . | No. of patients . | No. of evaluable patients . | CR . | PR . | SD . | PD . | PR + CR (% of evaluable patients) . |
|---|---|---|---|---|---|---|---|
| 100 | 5 | 4 | 0 | 0 | 0 | 4 | 0 (0) |
| 300 | 8 | 7 | 1 | 5 | 0 | 1 | 6 (86) |
| 500 | 17 | 14 | 3 | 6 | 3 | 2 | 9 (64) |
| 625 | 4 | 3 | 0 | 2 | 0 | 1 | 2 (67) |
| 300 to 625 | 29 | 24 | 4 | 13 | 3 | 4 | 17 (71) |
| Total | 34 | 28 | 4 | 13 | 3 | 8 | 17 (61) |
IL-12, ng/kg . | No. of patients . | No. of evaluable patients . | CR . | PR . | SD . | PD . | PR + CR (% of evaluable patients) . |
|---|---|---|---|---|---|---|---|
| 100 | 5 | 4 | 0 | 0 | 0 | 4 | 0 (0) |
| 300 | 8 | 7 | 1 | 5 | 0 | 1 | 6 (86) |
| 500 | 17 | 14 | 3 | 6 | 3 | 2 | 9 (64) |
| 625 | 4 | 3 | 0 | 2 | 0 | 1 | 2 (67) |
| 300 to 625 | 29 | 24 | 4 | 13 | 3 | 4 | 17 (71) |
| Total | 34 | 28 | 4 | 13 | 3 | 8 | 17 (61) |
KS responses to IL-12 analyzed by dose administered.
Numbers in parentheses are the major responses (partial plus complete responses) expressed as a percentage of evaluable patients.
CR indicates complete response; PR, partial response; SD, stable disease; and PD, progressive disease.